Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus HYDROCHLOROTHIAZIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus HYDROCHLOROTHIAZIDE INTENSOL.
HYDRO-RIDE vs HYDROCHLOROTHIAZIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic